EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Effectiveness and Safety of Orodispersible Budesonide for Eosinophilic Esophagitis: A Multicenter Real-World Study

Daria Maniero, Matteo Ghisa, Alessandro Bruschi, Greta Lorenzon, Luisa Bertin, Giorgia Giorgini, Emanuele Bendia, Marina Coletta, Roberto Penagini, Pierfrancesco Visaggi, Nicola de Bortoli, Edoardo Vespa und 20 weitere

Clinical Gastroenterology and Hepatology · 2026-04 · 24 (4) · 986-994

DOI: 10.1016/j.cgh.2025.08.033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-04. Verfasst von Daria Maniero und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Gastroenterology Unit, Azienda Ospedale Università Padova, P…. Hauptthemen laut MEDLINE: Budesonide, Eosinophilic Esophagitis, Anti-Inflammatory Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Topical corticosteroids represent one of the effective first-line treatment options for eosinophilic esophagitis (EoE), and therapy with budesonide orodispersible tablets (BOTs) has been recently approved for the treatment of EoE and showed great efficacy in randomized-controlled clinical trials, however real-life data are lacking. Thus, we aimed to evaluate the effectiveness of treatment with BOTs in adult EoE patients in a real-life setting. METHODS: In this prospective study, clinical, histologic, endoscopic, and safety measures were assessed. Patients underwent evaluation after the induction period (12 weeks) and up 1 year of treatment with BOTs. Dysphagia Symptom Questionnaires were used for symptoms; the Adult Eosinophilic Esophagitis Quality of Life questionnaire for quality of life; the Endoscopic Reference Score for endoscopic activity; eosinophilic peaks (eosinophils per high-power field) for histologic activity. RESULTS: A total of 233 patients were enrolled and 203 completed the assessments after 12 weeks. Deep histological remission was achieved by 84% of patients, as well as clinical remission, associated with an improvement in quality of life. Eighty-six patients concluded 1 year of treatment, and 78% were still in deep remission, while 15% experienced a loss of histological response at treatment tapering. Primary nonresponders were 8%, and secondary nonresponders were 3%. No serious adverse effects were recorded. Only mild side effects related to drug assumption were reported by 28 (12%) of 233 patients, and the most common were oral symptoms. CONCLUSIONS: Our real-world data confirm that BOTs are effective in inducing clinical and histologic remission in most EoE patients. The drug has a good safety profile, with side effects occurring only in a small number of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BudesonideEosinophilic EsophagitisAnti-Inflammatory AgentsHumansMaleFemaleAdultMiddle AgedProspective StudiesTreatment OutcomeQuality of LifeAdministration, OralSurveys and QuestionnairesYoung AdultAgedTabletsDrug-Related Side Effects and Adverse ReactionsAdolescentHistocytochemistry

Stichwörter der Autor:innen

Eosinophilic EsophagitisInflammationSteroidsTherapyType 2 Inflammation

Substanzen

BudesonideAnti-Inflammatory AgentsTablets

Autor:innen und Institutionen

  • Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Gastroenterology Unit, Azienda Ospedale Università Padova, Padua, Italy.
  • Gastroenterology Unit, Azienda Ospedale Università Padova, Padua, Italy.
  • Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
  • Department of Digestive System Diseases, Digestive Endoscopy and Chronic Inflammatory Bowel Diseases, Ospedali Riuniti di Ancona, Ancona, Italy.
  • Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Gastrointestinal Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Zitieren

APA

Maniero, D., Ghisa, M., Bruschi, A., Lorenzon, G., Bertin, L., Giorgini, G., Bendia, E., Coletta, M., Penagini, R., Visaggi, P., de Bortoli, N., Vespa, E., Barchi, A., Mari, A., Dilaghi, E., Annibale, B., Iovino, P., Di Feo, E., Caminati, M., …, & Savarino, E. V. (2026). Effectiveness and Safety of Orodispersible Budesonide for Eosinophilic Esophagitis: A Multicenter Real-World Study. Clinical Gastroenterology and Hepatology, 24(4), 986-994. https://doi.org/10.1016/j.cgh.2025.08.033

Vancouver

Maniero D, Ghisa M, Bruschi A, Lorenzon G, Bertin L, Giorgini G, et al. Effectiveness and Safety of Orodispersible Budesonide for Eosinophilic Esophagitis: A Multicenter Real-World Study. Clinical Gastroenterology and Hepatology. 2026;24(4):986-994. doi:10.1016/j.cgh.2025.08.033

BibTeX
@article{Maniero2026,
  author = {Maniero, Daria and Ghisa, Matteo and Bruschi, Alessandro and Lorenzon, Greta and Bertin, Luisa and Giorgini, Giorgia and Bendia, Emanuele and Coletta, Marina and Penagini, Roberto and Visaggi, Pierfrancesco and de Bortoli, Nicola and Vespa, Edoardo and Barchi, Alberto and Mari, Amir and Dilaghi, Emanuele and Annibale, Bruno and Iovino, Paola and Di Feo, Elvira and Caminati, Marco and Caldart, Federico and Russo, Salvatore and Marabotto, Elisa and Pasta, Andrea and Lovero, Rosa and Pisani, Antonio and Di Sabatino, Antonio and Lenti, Marco Vincenzo and Rossi, Carlo Maria and Merli, Stefania and Ribaldone, Davide Giuseppe and Bonazzi, Erica and Savarino, Edoardo Vincenzo},
  title = {Effectiveness and Safety of Orodispersible Budesonide for Eosinophilic Esophagitis: A Multicenter Real-World Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {986--994},
  doi = {10.1016/j.cgh.2025.08.033}
}
Kostenlos starten →